)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Karyopharm Therapeutics
Karyopharm Therapeutics (KPTI) investor relations material
Karyopharm Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Feb, 2026
Executive summary
Positioned for transformative late-stage clinical milestones in 2026, with Phase 3 readouts in myelofibrosis (March) and endometrial cancer (mid-year), aiming to expand the oncology franchise and commercial opportunities.
XPOVIO (selinexor) maintains a durable commercial base in multiple myeloma, is approved in over 50 countries, and is supported by a profitable U.S. commercial organization with growing global demand.
The company is preparing for a potential commercial launch in myelofibrosis, targeting a peak annual revenue opportunity of up to $1 billion.
Financial highlights
2025 total revenue was $146.1M, up slightly from $145.2M in 2024; Q4 2025 revenue was $34.1M, up from $30.5M in Q4 2024.
U.S. XPOVIO net product revenue reached $114.9M in 2025, with $32.1M in Q4 2025 (+9.6% YoY).
License and other revenue for 2025 was $31.2M, including $15M R&D reimbursement from Menarini (final year for this item).
R&D expenses for 2025 were $125.6M, down from $143.2M, and SG&A expenses were $105.2M, down from $115.4M, reflecting cost reduction initiatives.
Net loss for 2025 was $196.0M ($17.93/share), up from $76.4M ($9.41/share) in 2024, driven by non-cash items including a $62.4M loss on extinguishment of debt.
Year-end cash and investments totaled $64.1M, down from $109.1M at end of 2024.
Outlook and guidance
2026 total revenue guidance: $130–$150M, with U.S. XPOVIO net product revenue of $115–$130M.
R&D and SG&A expenses projected at $230–$245M for 2026.
Existing liquidity and expected revenues to fund operations into Q2 2026.
Novartis's MF plans: impact on US market entry?
XPORT-EC-042: how will safety profile improve?
What financing options are being evaluated?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Karyopharm Therapeutics earnings date
Q1 202611 May, 2026
Karyopharm Therapeutics
Next Karyopharm Therapeutics earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm Therapeutics develops therapeutic drug products based on an innovative drug delivery technology that has the potential to improve drug efficacy and safety in open label settings. Its lead product candidate, KPT-8602 for solid tumors and KPT-1203 for hematological malignancies, uses its proprietary Permeation Enhancing Sequence (PES)-based lipophilic doxorubicin (DOX) prodrug platform to develop novel therapeutics with potential clinical and commercial applications. Karyopharm Therapeutics is also developing KRN2300 to treat patients with multiple myeloma.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage